Feb 18, 2021
Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma
Feb 15, 2021
Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2020 Results Presentation and Webcast
Dec 21, 2020
Nordic Nanovector - Financial Calendar 2021
Dec 07, 2020
Nordic Nanovector to Present at DNB's 11th Annual Nordic Healthcare Conference
Dec 01, 2020
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma
Nov 30, 2020
Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'
Nov 19, 2020
Nordic Nanovector ASA: Results for the Third Quarter 2020
Oct 21, 2020
Nordic Nanovector ASA: Extraordinary general meeting held
Oct 19, 2020
Nordic Nanovector ASA - Streaming details for EGM
Sep 03, 2020
Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances
Aug 27, 2020
Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020
Aug 06, 2020
Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL
Jun 30, 2020
Nordic Nanovector to Amend PARADIGME Trial Protocol to Expand Eligible Patient Population
Jun 29, 2020
Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma
Jun 10, 2020
Nordic Nanovector ASA: Annual General Meeting Held
May 26, 2020
Nordic Nanovector ASA: Results for the First Quarter 2020
May 20, 2020
Nordic Nanovector ASA Announces Proposed Change of the Nomination Committee
May 20, 2020
Nordic Nanovector ASA: Notice of Annual General Meeting on 10 June 2020
May 14, 2020
Nordic Nanovector's Betalutin® Receives Positive Opinion for Orphan Drug Designation from EMA for Marginal Zone Lymphoma (MZL)
Apr 08, 2020
Nordic Nanovector Announces New Date for Annual General Meeting